Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vespula germanica venom protein
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intradermal, Epicutaneous
01
Overview
Vespula germanica venom protein is a standardized allergenic extract derived from the venom of the European wasp (Vespula germanica), commonly known as the German yellowjacket. It is primarily used in allergy testing and for immunotherapy in patients with IgE-mediated allergies to wasp stings. The extract contains a mixture of proteins that act as allergens and can provoke an immune response in sensitized individuals. Its mechanism of action involves controlled exposure to these allergens to induce immune tolerance or desensitization, thereby reducing allergic reactions upon subsequent natural exposures[1][2][6]. The product is available as a freeze-dried powder for reconstitution and subcutaneous injection[7]. It is included in multi-species vespid extracts for broader coverage against related species[6].
- Brand names
- Venomil
- Other names
- yellow jacket venom proteinhymenoptera venom diagnosticallergenic extract waspvespula spp. venom protein
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on Vespula germanica venom protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vespula germanica venom protein.